Objective Hematological treatment decisions in older adults with hematological malignancies are complex. Our objective is to study the impact of a comprehensive geriatric assessment on hematological treatment decision in older patients and the factors associated with change in treatment plan. Methods We conducted a cross‐sectional analysis of patients aged 65 years and above with hematological malignancies, hospitalized between 2008 and 2019 at the University Cancer Institute of Toulouse. They were assessed by a geriatrician/nurse team using a comprehensive geriatric assessment (CGA). A penalized logistic regression model with elastic net regularization was used to identify factors associated with change in hematological treatment plan. Results A total of 424 patients were included. Main hematological malignancies were lymphoma (36.1 %), acute myeloid leukemia (26.9 %) and myelodysplastic syndrome (19.8%). Change in hematological treatment plan was suggested after CGA for 92 patients (21.7%). Factors associated with change in treatment plan were functional impairment according to ADL and IADL scale, mobility impairment, the presence of comorbidity defined by the Charlson score >1 and increasing age. Conclusion A CGA has a significant impact on hematological treatment decision in older patients. Functional and mobility impairment, comorbidities and age are predictive factors of change in treatment plan.

Diffuse large B cell lymphoma (DLBCL) represents 30%-40% of adult non-Hodgkin lymphoma (NHL). 1 DLBCL is a highly aggressive disease, with a limited life expectancy without treatment and a poor prognosis in case of relapse or refractory disease. 2 Its incidence increases with age, with a median age of 70 years at diagnosis. 1 Considering population aging, an increased incidence is expected within the next few years. 3 R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Oncovin, Prednisone) regimen is widely used as a first-line treatment for this

No abstract

No abstract

No abstract